Study: NCT02475135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: A tablet containing Darunavir (DRV) 800 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: A tablet containing Darunavir (DRV) 800 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir alafenamide (FTC/TAF)
Description: A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir alafenamide (FTC/TAF)
Description: A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: A tablet containing cobicistat (COBI) 150 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: A tablet containing cobicistat (COBI) 150 mg will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat Breakfast
Description: High-fat breakfast will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Regular Breakfast
Description: Standardized regular breakfast will administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Regular Breakfast
Description: Standardized regular breakfast will administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Regular Breakfast
Description: Standardized regular breakfast will administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Regular Breakfast
Description: Standardized regular breakfast will administered.